TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03172156

Intervention type: GENETIC
Intervention: ctDNA detection
Description: To detect ctDNA in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)
Study: NCT03559699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance.~Part 2 (Fixed Dose Period): Optimized dose determined in Part 1.
Study: NCT05055882

Intervention type: OTHER
Intervention: children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital
Description: Comparison of Adult-Onset Still's disease phenotypes
Study: NCT00684827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI
Description: 1. Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~2. Arm #A~3. Xopenex HFA MDI, Pirbuterol HFA MDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic Albuterol followed by levalbuterol HFA MDI
Description: 1. Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~2. Arm #B~3. Pirbuterol HFA MDI, Xopenex HFA MDI
Study: NCT01833234

Intervention type: OTHER
Intervention: Interviews and questionnaires
Study: NCT02792023

Intervention type: OTHER
Group type: OTHER
Intervention: Immunochemical fecal occult blood test
Description: Participants will be provided with a single immunochemical fecal occult blood test. Participants will introduce a small sample of feces inside and bring the test to the hospital

Intervention type: OTHER
Group type: OTHER
Intervention: Immunochemical fecal occult blood test
Description: Participants will be provided with a single immunochemical fecal occult blood test. Participants will introduce a small sample of feces inside and bring the test to the hospital

Intervention type: DEVICE
Group type: OTHER
Intervention: Colonoscopy
Description: A colonoscopy (procedure performed using a scope design to examine the large bowel) will be offered to the participants

Intervention type: DEVICE
Group type: OTHER
Intervention: Colonoscopy
Description: A colonoscopy (procedure performed using a scope design to examine the large bowel) will be offered to the participants
Study: NCT02515955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Participants will receive minocycline 100 mg as capsule twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446 Matching Placebo
Description: Participants will receive placebo matching with JNJ 54175446 once daily orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446 Matching Placebo
Description: Participants will receive placebo matching with JNJ 54175446 once daily orally.
Study: NCT02792023

Intervention type: DEVICE
Group type: OTHER
Intervention: Upper endoscopy
Description: An upper endoscopy (procedure performed using a scope to examine the upper digestive tract) will be offered to the participants

Intervention type: DEVICE
Group type: OTHER
Intervention: Upper endoscopy
Description: An upper endoscopy (procedure performed using a scope to examine the upper digestive tract) will be offered to the participants
Study: NCT01364740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMP-300E
Description: Data collected from Level 3 device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-lab PSG
Description: Data collected from Type I In-Lab Polysomnography
Study: NCT00710463

Intervention type: DEVICE
Intervention: non invasive ventilation (Resmed VPAP III ST-A, Respironics Harmony)
Description: non invasive ventilation was performed with commercially available ventilators from the manufacturers Resmed and Respironics.
Study: NCT02215343

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat bran extract
Description: Patients will be provided with 15g of wheat bran extract (WBE) (Cargill R\&D Centre Europe).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Patients will be provided with a fish oil supplement (capsules), containing 3-4g of N-3 fatty acids (Axellus A/S, Ishøj, Denmark).
Study: NCT02247180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive rehabilitation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standardized cognitive training
Study: NCT00599690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epi-LASK
Description: 10 eyes of 10 patients underwent epi-LASK, epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
Study: NCT03025178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4Fr central venous catheter insertion
Description: The central venous catheter is placed at left internal jugular vein in infant, and its tip is confirmed by transthoracic echocardiography.
Study: NCT02515955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446 Matching Placebo
Description: Participants will receive placebo matching with JNJ 54175446 once daily orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446 Matching Placebo
Description: Participants will receive placebo matching with JNJ 54175446 once daily orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446 Matching Placebo
Description: Participants will receive placebo matching with JNJ 54175446 once daily orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446 Matching Placebo
Description: Participants will receive placebo matching with JNJ 54175446 once daily orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446 Matching Placebo
Description: Participants will receive placebo matching with JNJ 54175446 once daily orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446 Matching Placebo
Description: Participants will receive placebo matching with JNJ 54175446 once daily orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine
Description: Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine
Description: Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine
Description: Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine
Description: Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine
Description: Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine
Description: Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine
Description: Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
Study: NCT01998945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-based Cognitive Behavioral Therapy
Description: Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of exposure-based cognitive behavioral therapy, a time-limited treatment that focuses on confronting avoided memories and situations and identifying and managing distressing thoughts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Training
Description: Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of Relaxation Training, that focus on muscle relaxation and diaphragmatic breathing to address the physical symptoms of anxiety.
Study: NCT03365557

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Airway peak pressure
Description: Air was injected into LMA cuff during expiration phase to make intracuff pressure achieve the level of airway peak pressure. If there's any leakage, increase 5 cmH2O every time till there's no air leakage from the mouth.
Study: NCT04166084

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active ROM Exercises
Description: Active ROM exercises programme will include hip flexion-extention, hip abduction-adduction, hip internal-external rotation, knee flexion-extention and ankle dorsi-plantar flextion exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active ROM Exercises
Description: Active ROM exercises programme will include hip flexion-extention, hip abduction-adduction, hip internal-external rotation, knee flexion-extention and ankle dorsi-plantar flextion exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk Stabilization Exercises Training
Description: Trunk stabilization exercises training will be given under the supervision of a physiotherapist. This training exercises will include diphragmatic exrecises, posterior pelvic tilt exercises, abdominal streghtening exercises,
Study: NCT00687297

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vandetanib induction
Description: 100 mg daily by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vandetanib induction
Description: 100 mg daily by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: (75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: (75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vandetanib maintenance
Description: 300 mg daily by mouth
Study: NCT03006393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: One infusion of Infliximab (Remicade) will be administered intravenously (IV) at 5 mg/kg body weight over a two hour period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One infusion of placebo treatment will be administered intravenously (IV) over a two hour period.
Study: NCT03587415

Intervention type: DIAGNOSTIC_TEST
Intervention: preptin and amylin level
Description: we will take both of group blood samples to compare them serum preptin and amylin

Intervention type: DIAGNOSTIC_TEST
Intervention: preptin and amylin level
Description: we will take both of group blood samples to compare them serum preptin and amylin
Study: NCT01005030

Intervention type: OTHER
Intervention: Blood draw
Description: Blood draw, two tubes, used for isolation of cell-free blood plasma

Intervention type: OTHER
Intervention: Blood draw
Description: Blood draw, two tubes, used for isolation of cell-free blood plasma
Study: NCT03610009

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D ultrasound
Description: The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of conventional two-dimensional (2D) ultrasound.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SonoAVC
Description: The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of SonoAVC.
Study: NCT01841385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates method
Description: Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions. For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load.
Study: NCT03345706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective cerebral hypothermia
Description: Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Cooling will be initiated and targeted to reach ipsilateral nasal temperature of 27±2°C for 12 hours, followed by controlled rewarming.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular hypothermia
Description: Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Subjects will receive systemic hypothermia via ECMO at 33.5±0.5°C (33-34°C) for 48 hours at the same time.
Study: NCT03293043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NPV-EVLP
Description: Lungs deemed marginal based on standard lung donor criteria that meet study eligibility will be physiologically assessed during ex-vivo perfusion. NPV-EVLP of these lungs will be performed with the addition of numerous pre-determined additives. With respect to the decision of lung utilization post-EVLP, eligibility criteria listed in the Post-NPV-EVLP section of the trial will need to be met. Lungs will also be excluded if they are deemed unsuitable based on the clinical judgment of the lung transplant surgeon.
Study: NCT04050514

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: H-MAD with a hinge system according to Herbst
Description: The randomized grouping into blocks at a ratio of 1: 1 takes place over sealed envelopes containing the allocation key for the respective MAD. The assignment is stratified according to gender because gender is a strong predictor of sleep disorders and also temporomandibular dysfunctions Integration of the MAD (start of treatment) The laboratory-made MAD (F-MAD / H-MAD) is integrated and checked for a comfortable fit. The patient is instructed to always wear the splint during sleep.~All patients receive an extended guide to jaw gymnastics with the instruction to do it in the morning after waking up and in the evening before falling asleep.~Four weeks after incorporation, the titration phase begins, the slow adjustment of mandibular advancement to optimize sleep medical parameters while minimizing unwanted side effects.~Control appointments take place after four weeks, six months, one year and two years after insertion of the MAD

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H-MAD with a hinge system according to Herbst
Description: The randomized grouping into blocks at a ratio of 1: 1 takes place over sealed envelopes containing the allocation key for the respective MAD. The assignment is stratified according to gender because gender is a strong predictor of sleep disorders and also temporomandibular dysfunctions Integration of the MAD (start of treatment) The laboratory-made MAD (F-MAD / H-MAD) is integrated and checked for a comfortable fit. The patient is instructed to always wear the splint during sleep.~All patients receive an extended guide to jaw gymnastics with the instruction to do it in the morning after waking up and in the evening before falling asleep.~Four weeks after incorporation, the titration phase begins, the slow adjustment of mandibular advancement to optimize sleep medical parameters while minimizing unwanted side effects.~Control appointments take place after four weeks, six months, one year and two years after insertion of the MAD
Study: NCT04635657

Intervention type: OTHER
Intervention: Long-term Cognitive testing
Description: These patients will undergo their standard of care cognitive testing at baseline, six weeks post-operatively and one year post-operatively.
Study: NCT00201825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 36 mg/m2 IV weekly for 3 weeks every 4 weeks.
Study: NCT03419741

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Clinical Research System
Description: Transcranial Magnetic Stimulation Clinical Research System is a US FDA approved treatment system for depression. The treatment research system includes motor threshold TMS coil, active TMS coil and sham TMS coil.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Clinical Research System
Description: Transcranial Magnetic Stimulation Clinical Research System is a US FDA approved treatment system for depression. The treatment research system includes motor threshold TMS coil, active TMS coil and sham TMS coil.
Study: NCT00916994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpaceGuard Balloon
Description: Positioning of the balloon into the subacromial space between the humerus head and the acromion
Study: NCT04284033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Wear Infusion Set
Description: For two of the 4 weeks, the Extended Wear insulin infusion set will be used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Wear Infusion Set
Description: For two of the 4 weeks, the Extended Wear insulin infusion set will be used
Study: NCT03695185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravagalimab 600 mg
Description: Ravagalimab 600 mg was administered intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravagalimab 300 mg
Description: Ravagalimab 300 mg was administered subcutaneously (SC).
Study: NCT04284033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Infusion Set
Description: For two of the 4 weeks, the standard insulin infusion set will be used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Infusion Set
Description: For two of the 4 weeks, the standard insulin infusion set will be used
Study: NCT03574987

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
Study: NCT01432236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 300 or 450 mg/day dosed BID ( twice a day) for 14 weeks; 150 mg/day starting dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules twice a day for 14 weeks
Study: NCT01888367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFA-02 Antibiotic Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DFA-02 Placebo Gel
Study: NCT02863406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage
Description: Bronchoalveolar lavage in order to determine rate of dust

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage
Description: Bronchoalveolar lavage in order to determine rate of dust
Study: NCT01853397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liposonix System (Model 2)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liposonix System (Model 2)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liposonix System (Model 2)
Study: NCT01263145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03260452

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal subcutaneous biopsies and Blood test
Description: Abdominal subcutaneous biopsies and blood test for each volunteer.
Study: NCT01670877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Study: NCT01853397

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Liposonix System (Model 2)
Study: NCT00085189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen
Description: Given SC
Study: NCT01670877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Study: NCT03365557

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Airway peak pressure
Description: Air was injected into LMA cuff during expiration phase to make intracuff pressure achieve the level of airway peak pressure. If there's any leakage, increase 5 cmH2O every time till there's no air leakage from the mouth.
Study: NCT03541928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSV-Tk
Description: Injection of the HSV-tk gene therapy product in four quadrants of prostate to enhance the immune system via bystander effect in which cytotoxicity is conferred to non-transduced neighboring cells. In vivo bystander effects are likely due to a combination of host immunological responses and to gap junction-mediated transport of phosphorylated prodrug metabolites to surrounding cells.
Study: NCT01670877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: -Optional at baseline and disease progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: -Optional at baseline and disease progression